



Article

Identifying the Extended Spectrum β -Lactamase in *Acinetobacter Baumannii* From Wounds

Ali Hussein Mohammed^{1*}

1. Department of Pathological Analytics, College of Medical Applied Science, University of Shatra, Thi-Qar, Iraq

* Correspondence: Alihussein@shu.edu.iq

Abstract: Extended spectrum β -lactamases (ESBLs) are enzymes encoded by mobile genes that confer resistance to many antibiotics by hydrolyzing cephalosporins and penicillins. Infections caused by Gram-negative bacteria like *Acinetobacter baumannii*, which can produce ESBLs, pose significant treatment challenges and are linked to increased morbidity and mortality. However, data on ESBL-producing *A. baumannii* in clinical specimens remains limited. This study aimed to identify *A. baumannii* isolates from clinical samples and assess their antibiotic resistance, particularly ESBL production. One hundred clinical specimens collected between October 2023 and May 2024 were cultured and analyzed using biochemical assays. Sixteen *A. baumannii* isolates were identified, with only two producing ESBLs. These ESBL-producing isolates showed high resistance to multiple antibiotics, including amoxicillin (100%) and cefotaxime (87.5%). The findings highlight the critical need for vigilant infection control and antibiotic stewardship to prevent the spread of multidrug-resistant *A. baumannii* in clinical settings.

Keywords: ESBL, *Acinetobacter baumannii*, Antibiotic resistance, Multidrug-resistant bacteria, Infection control

1. Introduction

The management of patients in hospitals and communities is currently faced with a significant therapeutic challenge. This is due to a complex and rapidly evolving group of enzymes called extended-spectrum β -lactamases (ESBLs), which are plasmid-mediated [1]. These enzymes are encoded by movable genes [2]. These often genes encode resistances to a variety of antibiotics, such as sulfamethoxazole-trimetroprime, amino glycosides, tetracyclines, fluoroquinolones, and cephalosporins [3]. Liakopoulos et al. (2016) state that ESBL can hydrolyze extended-spectrum cephalosporins that have an oxymino side chain. These cephalosporins include ceftriaxone, cefotaxime, cephodoxime and ceftazidime. *Acinetobacter baumannii* is an opportunistic pathogen that has become more common over the past 20 years.

It is a significant species that plays a role in nosocomial infections, which can include wound infections, pneumonia, urinary tract infections, and septicemia [4,5]. The use of broad-spectrum antibiotics has increased during the past several years due to an increase in isolates that have been shown to be resistant to numerous medications. It is a major therapeutic challenge to treat infections caused on by this bacterium [6]. Reports have mostly identified Ambler class A clavulanic acid-inhibited ESBLs as the majority of

Citation: Ali Hussein Mohammed. Identifying the Extended Spectrum β -Lactamase in *Acinetobacter Baumannii* From Wounds. Central Asian Journal of Medical and Natural Science 2024, 5(4), 990-995.

Received: 29th August 2024

Revised: 29th Sept 2024

Accepted: 6th Oct 2024

Published: 13th Oct 2024



Copyright: © 2024 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

Acinetobacter expanded-spectrum β -lactamases [7]. Aim of this investigation was to determine ESBLs enzyme and assess antibiotic susceptibility in Acinetobacter baumannii that was isolated from clinical wound specimens in Nasiriyah City.

2. Materials and Methods

Samples Collection

All Samples collected from patients hospitalized or readmitted to Nasiriyah Hospital in Nasiriyah City between October 2023 and May 2024 were used in this study. Samples (n = 100) were taken from wounds using swabs.

Identification of Acinetobacter

The specimens in the microbiology lab were grown on MacConkey agar and incubated under aerobic conditions for a whole night at 37°C in bacteriological incubators, based on the morphological characteristics of the colonies and a Gram stain microscopy analysis. The Acinetobacter isolates were diagnosed using biochemical tests such as Oxidase, Urease, Methyl red, Voges proskauer, Indole, Simon citrate, Kliglers iron agar tests, and string test in order to distinguish Acinetobacter from other gram negative bacteria.

Bacterial Susceptibility Detection

Each isolate underwent a susceptibility test against sixteen antibacterial agents (Bioanalyse, Turkey). Based on the Kirby-Bauer disc diffusion method, the testing findings determined the interdependence among the different species of Acinetobacter baumannii (Kumari et al., 2023). The antibiotic disc inhibition zone was evaluated in accordance with CLSI recommendations (2014). Amikacin 30 μ g (AK), Azithromycin 30 μ g (ATM), Gentamicin 10 μ g (GN), Netilmicin 30 μ g (NET), Imipenem 10 μ g (IMP), Meropenem 10 μ g (MEM), Ceftazidim 30 μ g (CAZ), Ceftriaxone 30 μ g (CRO), Cefotaxime 30 μ g (CTX), Ciprofloxacin 5 μ g (CIP), Norfloxacin 10 μ g (NOR), Naldixic acid 30 μ g (NA), Carbencillin 100 μ g (PY), Amoxicillin-clavulanic acid 20 μ g (AUG), Amoxicillin 10 μ g (AX) and Nitrofurantion 300 μ g (F)

ESBLs detection

A sterile swab was dipped into the suspension of A. baumannii suspension, the turbidity met 0.5 McFarland standards, after that, Mueller-Hinton agar plate was inoculated in three different directions. An amoxicillin-clavulanate disc 30 μ g was put in the middle of the agar plate. One disc containing 30 μ g ceftazidime was set 25mm away of amoxicillin-clavulanate, while cefotaxime 30 μ g was put 25mm away on the other side of amoxicillin-clavulanate. After an overnight incubation period at 37°C, the plates were considered to have produced ESBLs if inhibition zone of cefotaxime, clavulanate, amoxicillin-clavulanate disc, or both, expanded [8].

3. Results

Our results showed there are 16% of samples positive for bacterial growth of Acinetobacter, while 84% of samples are negative for growth.

Antibiotic Susceptibility and Detection of ESBLs

Acinetobacter isolates showed strong resistance to ceftazidime, carbenicillin, azithromycin, and amoxicillin. Ceftriaxone, gentamicin, cefotaxime, nitrofurantoin, amoxicillin-clavulanic acid, naldixic acid, and norfloxacin were the next susceptible antibiotics [9]. The majority of the identified Acinetobacter was discovered to be susceptible to ciprofloxacin, imipenem, amikacin, meropenem, and netilmicin, as shown in the table 1 and figure 2.

The presence of ESBLs enzymes was tested in all isolates of *A. baumannii* (n = 16). Two (12.5%) isolates were positive for ESBLs as well as were confirmed as multidrug resistance isolates which were resistant to four classes of antimicrobials [10]. Additionally, were not found in all ESBLs production isolates resistant to all classes of antibiotics, to be considered as extensive or pandrug resistance isolates figure 1.



Figure 1. The production of ESBLs is demonstrated through the extension of the inhibition zone between: AUG and CTX; AUG and CAZ, or both.

Table 1. Patterns of antibiotic susceptibility in isolates of *Acinetobacter baumannii* (n=16)

Antimicrobial	Susceptible(%)	Intermediate(%)	Resistant(%)
Amikacin	8(50)	3(18.75)	5(31.25)
Ciprofloxacin	4(25)	2(12.5)	8(50)
Imipenem	12(75)	0	4(25)
Meropenem	12(75)	0	4(25)
Ceftriaxone	1(6.25)	1(6.25)	14(87.5)
Gentamicin	2(12.5)	1(6.25)	13(81.25)
Cefotaxime	1(6.25)	1(6.25)	14(87.5)
Norfloxacin	5(31.25)	1(6.25)	10(62.5)
Nalidixic acid	4(25)	0	12(75)
Netilmicin	12(75)	0	4(25)
Carbencillin	2(12.5)	0	14(87.5)

Amoxicillin-clavulanic acid	1(6.25)	3(18.75)	12(75)
Amoxicillin	0	0	16(100)
Ceftazidim	1(6.25)	1(6.25)	14(87.5)
Nitrofurantion	1(6.25)	1(6.25)	14(87.5)
Azithromycin	1(6.25)	1(6.25)	14(87.5)



Figure 2. Show the resistance of *Acinetobacter baumannii* for antibiotics

4. Discussion

In hospitals and the community in general, antimicrobial resistance has grown to be an ongoing medical and public health concern [11]. The patterns of antibiotic susceptibility will therefore be helpful for determining which antibiotic to use and subsequently, reducing hospitalizations, morbidity, and mortality. Reasonable antimicrobial resistance guidelines will benefit from this information. However, due to a shortage of resources, these data or information are rare or unavailable in many of Iraqi provinces; similarly, in Al-Nasiriyah City, the data or information on resistance of antimicrobial among bacterial pathogens is random and inadequate [12].

The prevention and infections treatment that caused by *A. baumannii*, that makes the ES β Ls enzyme, has recently received interest [13]. ES β L-producing strains have been reported from a number of locations across the world, including Iraq, Palestine, Europe, North America, and China [14]. The following factors were involved in the rise in isolate resistance: Long-term hospitalization, the use of last-resort medications, the transfer of susceptible isolates to other patients, susceptible isolates acquired a plasmids encoding antibiotic resistance genes, following this, by way of patient-to-patient transfer, stabilize these resistance isolates [15].

Most ESBLs are generated as a result of mobile genes that are usually coding for resistance against various medications such as aminoglycosides and fluoroquinolones, as well as cephalosporins [16]. ESBLs are known to be present in gram-negative bacteria like *Acinetobacter*, which are broadly distributed in Iraq [17].

According to Rodrigues et al. (2004), out of 286 Gram-negative isolates, *E. coli* and *Klebsiella* were the main producers of ESBLs, then followed by *Enterobacter* and *Acinetobacter* spp [18]. The analysis of this study shows that the susceptibility of all *Acinetobacter* isolates tested to various antibiotics indicates that isolates have a high rate of resistance to commonly used antibiotics, as in table 1 explains the antimicrobial susceptibility results [19,20]. According to results of the Al-Shara (2013) study conducted in the city of Najaf, *A. baumannii* is resistant to both ceftriaxone (51.8%) and ceftazidime (60.5%), two third-generation cephalosporins [21].

Shali (2012) in Sulaimani city show there are multidrug resistance to various antibiotics is present in all isolates. The percentages of resistant were noted for each isolate; the highest rate of resistance was observed against ampicillin (100%) and the lowest rate against imipenem (57.1%) [22]. *A. baumannii*'s cephalosporin resistance in Iraq has been reported by AL-Kadhmi (2015) all *A. baumannii* isolates were 100% resistant to ceftazidime, cefepime, and cefotaxime. Asaad, et al. (2013) revealed 91% of *A. baumannii* in Saudi Arabia 2013 were resistant to ceftazidime [23].

5. Conclusion

Conclusion wounds could contain *A. baumannii* that have ESBL and are resistant to multiple classes of antibiotics; therefore, this needs to be taken into consideration when selecting the appropriate antibiotic to prevent diffusion of such resistant bacteria.

REFERENCES

- [1] F. S. Al-Mayahi, "Distribution of CTXM Beta-Lactamases (ESBL) of Uropathogenic Isolates of *E. coli* in Al-Diwaniya City," Ph.D. dissertation, Univ. of Al-Kadeseiya, Iraq, 2013.
- [2] J. M. R. Al-Shara, "Phenotypic and Molecular Detecting of Carbapenem Resistant *Pseudomonas Aeruginosa* in Najaf Hospitals," Ph.D. dissertation, Faculty of Science, Univ. of Kufa, Iraq, 2013.
- [3] R. Kumari, K. Saurabh, S. Kumar, N. Kumari, R. Kumari Sr., and K. Saurabh, "Comparative Evaluation of Broth Microdilution with Disc Diffusion and VITEK 2 for Susceptibility Testing of Colistin on Multidrug-Resistant Gram-Negative Bacteria," *Cureus*, vol. 15, no. 12, 2023.
- [4] M. Chatterjee, M. Banerjee, S. Guha, A. Lahiri, and K. Karak, "Study of Drug Urinary Isolates in an Urban Hospital Setting in Eastern India," *Sri Lankan J. Infect. Dis. Chemother.*, vol. 55, no. 1, pp. 349-354, 2011.
- [5] Clinical and Laboratory Standards Institute, "Performance Standards for Antimicrobial Susceptibility Testing," 20th Informational Supplement, Approved Standard M07-A8, Wayne, PA, 2010.
- [6] Clinical and Laboratory Standards Institute, "Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement," CLSI document M100-S24, Wayne, PA, 2014.
- [7] A. Liakopoulos, D. Mevius, and D. Ceccarelli, "A Review of SHV Extended-Spectrum β -Lactamases: Neglected Yet Ubiquitous," *Frontiers in Microbiology*, vol. 7, 2016.
- [8] A. Gouby, M. J. Carles-Nurit, N. Bouziges, et al., "Use of Pulsed-Field Gel Electrophoresis for Investigation of Hospital Outbreaks of *Acinetobacter Baumannii*," *J. Clin. Microbiol.*, vol. 30, no. 6, pp. 1588-1591, 1992.
- [9] R. A. Bonomo, " β -Lactamases: A Focus on Current Challenges," *Cold Spring Harbor Perspect. Med.*, vol. 7, no. 1, 2017.
- [10] D. M. Livermore and D. F. Brown, "Detection of β -Lactamase-Mediated Resistance," *J. Antimicrob. Chemother.*, vol. 48, no. 1, pp. 59-64, 2001.

- [11] M. Meric, A. Willke, C. Caglayan, and K. Toker, "Intensive Care Unit-Acquired Infection: Incidence, Risk Factors and Associated Mortality in a Turkish University Hospital," *Jpn. J. Infect. Dis.*, vol. 58, no. 5, pp. 297-302, 2005.
- [12] L. Poirel, R. A. Bonnin, and P. Nordmann, "Genetic Support and Diversity of Acquired Extended-Spectrum β -Lactamases in Gram-Negative Rods," *Infect. Genet. Evol.*, vol. 12, no. 5, pp. 883-893, 2012.
- [13] R. Nugent, E. Back, and A. Beith, *The Race Against Drug Resistance*, Washington, DC: Center for Global Development, 2010.
- [14] P. Owlia, L. Azimi, A. Gholami, et al., "ESBL- and MBL-Mediated Resistance in *Acinetobacter Baumannii*: A Global Threat to Burnt Patients," *Infez. Med.*, vol. 20, no. 3, pp. 182-187, 2012.
- [15] A. Y. Peleg, H. Seifert, and D. L. Paterson, "*Acinetobacter Baumannii*: Emergence of a Successful Pathogen," *Clin. Microbiol. Rev.*, vol. 21, no. 3, pp. 538-582, 2008.
- [16] F. Perez, A. M. Hujer, K. M. Hujer, et al., "Global Challenge of Multidrug-Resistant *Acinetobacter Baumannii*," *Antimicrob. Agents Chemother.*, vol. 51, no. 10, pp. 3471-3484, 2007.
- [17] M. C. Rodrigues, P. Joshi, S. H. Jani, M. Alphonse, R. Radhakrishnan, and A. Mehta, "Detection of B-Lactamases in Nosocomial Gram-Negative Clinical Isolates," *Indian J. Med. Microbiol.*, vol. 22, pp. 247-250, 2004.
- [18] A. B. Remy, P. N. Patrice, A. P. Anais, et al., "Carbapenem-Hydrolyzing GES-Type Extended-Spectrum β -Lactamase in *Acinetobacter Baumannii*," *Antimicrob. Agents Chemother.*, vol. 55, no. 1, pp. 349-354, 2011.
- [19] K. S. Thompson, "Extended-Spectrum β -Lactamases, AmpC, and Carbapenemase Issues," *J. Clin. Microbiol.*, vol. 48, no. 4, pp. 1019-1025, 2010.
- [20] D. Yong, J. H. Shin, S. Kim, et al., "High Prevalence of PER-1 Extended-Spectrum β -Lactamase Producing *Acinetobacter* spp. in Korea," *Antimicrob. Agents Chemother.*, vol. 47, no. 5, pp. 1749-1751, 2003.
- [21] N. A. Al-Kadhmi, "Multidrug-Resistant *Pseudomonas Aeruginosa* and *Acinetobacter Baumannii* Isolated from Patients' Wounds," Higher Diploma Report, Genetic Engineering and Biotechnology Institute for Postgraduate Studies, Univ. of Baghdad, Iraq, 2015.
- [22] A. M. Asaad, M. S. Al-Ayed, and M. A. Qureshi, "Emergence of Unusual Nonfermenting Gram-Negative Nosocomial Pathogens in a Saudi Hospital," *Jpn. J. Infect. Dis.*, vol. 66, pp. 507-511, 2013.
- [23] A. A. Shali, "Identification of Multidrug-Resistant Genes in *Acinetobacter Baumannii* in Sulaimani City, Kurdistan Regional Government of Iraq," *Asian J. Med. Sci.*, vol. 4, no. 5, pp. 179-183, 2012.